USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates

Group 1: Earnings Performance - USANA Health Sciences reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.54 per share, and up from $0.54 per share a year ago, representing an earnings surprise of +37.04% [1] - The company posted revenues of $235.85 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.73%, compared to year-ago revenues of $212.87 million [2] - Over the last four quarters, USANA has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - USANA Health shares have declined approximately 15.6% since the beginning of the year, while the S&P 500 has gained 7.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.65 on revenues of $225.82 million, and for the current fiscal year, it is $2.61 on revenues of $946.98 million [7] Group 3: Industry Context - The Medical - Drugs industry, to which USANA belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact USANA's stock performance [5] - Another company in the same industry, Aquestive Therapeutics, is expected to report a quarterly loss of $0.18 per share, reflecting a significant year-over-year decline [9]